Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Please provide your email address to receive an email when new articles are posted on . Steven Yeh, MD, of Truhlsen Eye Institute, University of Nebraska Medical Center, said by 4 weeks, patients with ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

The treatment was approved in October 2021 and is the first FDA-approved therapy to treat macular edema associated with uveitis via injection to the suprachoroidal space, which provides a more ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach. What are the ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...